SCHEMBL12929462

SCHEMBL12929462

CCOC(=O)c1cnc(-c2ccccc2Cl)nc1N(CC)CC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.58
▸ KDM4E B2RXH2 1/20 0.58
▸ SMN1; SMN2 Q16637 4/20 0.57
▸ LMNA P02545 3/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ MAPT P10636 3/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ ATM Q13315 1/20 0.48
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ TP53 P04637 1/20 0.47
▸ FOS P01100 3/20 0.46
▸ JUN P05412 3/20 0.46
▸ NFKB1 P19838 3/20 0.46
▸ NFKB2 Q00653 3/20 0.46
▸ RELA Q04206 3/20 0.46
▸ CYP1A2 P05177 4/20 0.46
▸ POLB P06746 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CYP2C9 P11712 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12929671 0.90 ALDH1A1 (0.71) ALDH1A1KDM4ESMN1; SMN2LMNAALOX15
SCHEMBL12929723 0.88 ALDH1A1 (0.59) ALDH1A1KDM4ESMN1; SMN2LMNAALOX15
SCHEMBL12929679 0.87 ALDH1A1 (0.69) ALDH1A1KDM4ESMN1; SMN2LMNAALOX15
SCHEMBL12929575 0.85 ALDH1A1 (0.56) ALDH1A1KDM4ESMN1; SMN2LMNAALOX15
SCHEMBL12929634 0.83 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2LMNAALOX15MAPT
SCHEMBL12929573 0.82 ALDH1A1 (0.70) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL12929438 0.81 ALDH1A1 (0.60) ALDH1A1KDM4ESMN1; SMN2LMNAMAPT
SCHEMBL12929579 0.81 ALDH1A1 (0.58) ALDH1A1KDM4ESMN1; SMN2LMNAALOX15
SCHEMBL12929596 0.79 ALDH1A1 (0.65) ALDH1A1SMN1; SMN2LMNAALOX15MAPT
SCHEMBL12929583 0.78 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2LMNAALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 — — US disclosed
US-8324220-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-04 — — US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 — — US disclosed
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-01-06 — — US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 — — US disclosed
US-7816529-B2 Pyrimidines useful as modulators of voltage-gated ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003814-A1 PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS KCNJ1, KCNJ11, TRPV1 ALDH1A1 2361/4885KDM4E 1948/4885SMN1; SMN2 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback